SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-012075
Filing Date
2022-05-04
Accepted
2022-05-04 16:06:47
Documents
14
Period of Report
2022-04-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47663
2 ex99-1.htm EX-99.1 20643
3 ex99-1_001.jpg GRAPHIC 5765
  Complete submission text file 0001493152-22-012075.txt   257442

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE qlgn-20220429.xsd EX-101.SCH 3042
5 XBRL LABEL FILE qlgn-20220429_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE qlgn-20220429_pre.xml EX-101.PRE 22601
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3499
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

IRS No.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 22891516
SIC: 2834 Pharmaceutical Preparations